Wasatch Advisors LP Trims Stock Holdings in Artivion, Inc. $AORT

Wasatch Advisors LP lowered its stake in Artivion, Inc. (NYSE:AORT) by 23.5% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 156,388 shares of the company’s stock after selling 48,055 shares during the quarter. Wasatch Advisors LP owned about 0.32% of Artivion worth $5,727,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the stock. Aster Capital Management DIFC Ltd increased its holdings in Artivion by 402.3% in the 3rd quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock worth $27,000 after acquiring an additional 519 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in Artivion during the third quarter valued at approximately $27,000. Rockefeller Capital Management L.P. lifted its holdings in Artivion by 150.0% during the fourth quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock valued at $30,000 after purchasing an additional 399 shares in the last quarter. Larson Financial Group LLC boosted its position in shares of Artivion by 148.5% in the fourth quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock worth $43,000 after purchasing an additional 563 shares during the period. Finally, USA Financial Formulas boosted its position in shares of Artivion by 163.5% in the fourth quarter. USA Financial Formulas now owns 1,133 shares of the company’s stock worth $52,000 after purchasing an additional 703 shares during the period. 86.37% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, SVP Andrew M. Green sold 44,001 shares of the stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $20.70, for a total value of $910,820.70. Following the transaction, the senior vice president owned 60,259 shares of the company’s stock, valued at $1,247,361.30. This represents a 42.20% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.30% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently weighed in on AORT shares. Weiss Ratings cut shares of Artivion from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, June 8th. Canaccord Genuity Group reiterated a “buy” rating and set a $36.00 target price on shares of Artivion in a research report on Tuesday, June 16th. Wall Street Zen cut Artivion from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Citizens Jmp cut their price objective on shares of Artivion from $53.00 to $48.00 and set a “market outperform” rating for the company in a report on Friday, May 8th. Finally, LADENBURG THALM/SH SH raised shares of Artivion from a “neutral” rating to a “buy” rating and set a $42.00 target price for the company in a research note on Friday, April 10th. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $44.17.

Artivion Trading Up 4.3%

Shares of NYSE AORT opened at $23.62 on Friday. The company has a market cap of $1.15 billion, a price-to-earnings ratio of 98.44 and a beta of 1.26. Artivion, Inc. has a fifty-two week low of $19.16 and a fifty-two week high of $48.25. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.80 and a current ratio of 3.86. The business’s 50 day moving average price is $26.00 and its 200-day moving average price is $35.33.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.